黄葵胶囊通过保护足细胞损伤和抑制JAK/STAT信号减轻多柔比星诱导的蛋白尿
该研究通过多柔比星诱导蛋白尿小鼠模型和MPC-5足细胞损伤模型,探究黄葵胶囊(HKC)降低蛋白尿的机制。结果显示HKC连续给药三周呈剂量依赖性改善肾功能与病理损伤,上调足细胞标志物Nephrin和Podocin,并抑制JAK2/STAT3和PI3K/Akt通路磷酸化。
要点
- 黄葵胶囊剂量依赖性减轻多柔比星诱导的肾损伤和蛋白尿。
- HKC通过上调Nephrin和Podocin保护足细胞滤过屏障。
- 木犀草素-7-O-葡萄糖醛酸苷(Hibifolin)抑制JAK2/STAT3和PI3K/Akt通路。
核心结论
- 黄葵胶囊可能通过保护足细胞损伤及抑制JAK2/STAT3和PI3K/Akt通路来改善蛋白尿。
研究设计与样本
- 体内建立多柔比星诱导的蛋白尿小鼠模型,体外建立MPC-5足细胞损伤模型。
主要发现
- HKC连续给药三周剂量依赖性改善肾功能和组织病理学损伤。
- HKC上调足细胞Nephrin和Podocin表达,体外逆转多柔比星导致的异常表达。
- Hibifolin被鉴定为HKC中最活跃的成分,抑制JAK2/STAT3和PI3K/Akt通路磷酸化。
- AG490(选择性JAK2抑制剂)进一步证实Hibifolin参与调节JAK2/STAT3。
临床怎么用
- 黄葵胶囊可作为慢性肾脏病伴蛋白尿的辅助治疗,其机制涉及足细胞保护和JAK/STAT通路抑制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Huangkui capsule (HKC), a Chinese patent medicine, has been widely used in China as adjuvant therapy for chronic kidney disease (CKD). It displays superior anti-proteinuria efficacy than losartan in patients with CKD at stages 1-2, however, the mechanism of HKC alleviating proteinuria has not been well elucidated. AIM OF THE STUDY: This study aims to confirm the therapeutic effect and investigate associated underlying mechanism of HKC against proteinuria by in vivo and in vitro experiments. MATERIALS AND METHODS: We established a doxorubicin (DOX) induced proteinuria mouse model to evaluate kidney function by biochemical markers measurement and to observe histopathological alterations by hematoxylin and eosin (H&E), Masson's trichrome and Periodic Acid-Schiff (PAS)-stained sections of renal, respectively. Moreover, the expressions of Nephrin and Podocin were measured by immunohistochemistry (IHC) and western blotting analysis to investigate podocyte damage. Furthermore, we established Mouse Podocyte Clone-5 (MPC-5) injury model to identify the active components of HKC against podocyte damage by detecting the expressions of Nephrin, Podocin, and ZO-1 proteins. At last, the key protein levels of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway were assessed by western blotting analysis to explore the underlying mechanism of HKC against proteinuria. RESULTS: Our results showed that HKC administration for three consecutive weeks dose-dependently ameliorated both renal function and histopathological damages, elevated the expressions of Nephrin and Podocin, the pivotal molecules maintaining filtration function of the podocyte, indicating the promising protective effect against podocyte injury under DOX exposure. Consistently, in vitro experiments showed HKC administration effectively reversed the abnormal expressions of Nephrin and Podocin in MPC-5 cells treated with DOX, suggesting its protective effect against podocyte injury to maintain filtration barrier integrity. In addition, Hibifolin was identified as the most active ingredients in HKC, which suppressed upstream JAK2/STAT3 and PI3K/Akt pathway phosphorylation to maintain the structural and functional integrity of podocyte filtration barrier. Of note, AG490, a selective JAK2 inhibitor, was used to further affirm the role of Hibifolin involving in regulation JAK2/STAT3. CONCLUSIONS: Our study suggested that HKC may protect podocytes via JAK2/STAT3 and PI3K/Akt pathway to display its effects of ameliorating proteinuria.
引用
- Zhao L, Han S, Chai C, et al. Huangkui capsule alleviates doxorubicin-induced proteinuria via protecting against podocyte damage and inhibiting JAK/STAT signaling. J Ethnopharmacol. 2023. PMID: 36608778. doi:10.1016/j.jep.2023.116150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。